A5011420554- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Palliative Care and End-of-Life Issues
- Ethics in Clinical Research
- Geriatric Care and Nursing Homes
- Frailty in Older Adults
- Technology Use by Older Adults
- Elder Abuse and Neglect
- Healthcare Decision-Making and Restraints
- Neurobiology of Language and Bilingualism
- Aging and Gerontology Research
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Practices and Patient Outcomes
- Health and Medical Research Impacts
- Psychiatric care and mental health services
- Ginkgo biloba and Cashew Applications
- Mobile Health and mHealth Applications
- Health disparities and outcomes
- Health, Environment, Cognitive Aging
- Functional Brain Connectivity Studies
- Schizophrenia research and treatment
- Participatory Visual Research Methods
- Folate and B Vitamins Research
- Diet and metabolism studies
- Mental Health and Psychiatry
Icahn School of Medicine at Mount Sinai
2014-2024
James J. Peters VA Medical Center
2009-2022
Mount Sinai Hospital
2015
Australia Bioinformatics Resource
2013
Human studies on low-dose resveratrol are scarce. This study aims to evaluate the safety, tolerability, and efficacy of an oral preparation resveratrol, glucose, malate (RGM) in slowing progression Alzheimer's disease (AD).Thirty-nine subjects with mild moderate AD who were free life-threatening did not have contraindications use product screened. Progression was measured by change cognitive portion Disease Assessment Scale-cognitive subscale. Secondary outcomes included Clinician's Global...
Background:Subjective cognitive complaint is a sensitive marker of decline. Objective:This study aimed to (1) examine reliability subjective using the Cognitive Function Instrument (CFI), and (2) assess utility CFI detect decline in non-demented elders . Methods:Data from four-year longitudinal at multiple Alzheimer's Disease Cooperative Study (ADCS) sites were extracted (n = 644). Of these, 497 had Clinical Dementia Rating (CDR) global scores 0 147 CDR 0.5. Mean age education 79.5±3.6...
Objective: In New York City in 2020 the pandemic shut down in-person research. Icahn School of Medicine’s Alzheimer’s Disease Research Center transitioned longitudinal evaluations from to telephone enhance equity access. We assessed diverse research participants’ and clinical coordinators’ (CRC) satisfaction with remote evaluation examined sociodemographic, cognitive, behavioral factors that might impact satisfaction. Methods: Data collected: 241 participants Clinical Dementia Rating (CDR) =...
Understanding of the natural history apathy and its impact on patient function is limited. This study examines, in a large, national sample Alzheimer's disease (AD) patients with long follow-ups: (1) prevalence, incidence, persistence apathy, (2) across dementia severity.A longitudinal 9823 well-characterized AD National Coordinating Center Uniform Data Set.Apathy was highly prevalent severity cumulative prevalence 48%, 74%, 82% Clinical Dementia Rating (CDR) 0.5, 1.0, 2.0, respectively....
Family members incur substantial financial costs during the course of caring for an individual with Alzheimer's disease. Much this cost is associated time spent in caregiving tasks, including supervision and communication patient, assisting activities daily living. We have previously reported on cross sectional reliability validity a scale that measures caregiving, Caregiver Activity Survey (CAS). This study extends our results to longitudinal instrument. Forty-four outpatients disease who...
In dementia trials, minority participation is low. We assessed attitudes toward research in a community based urban poor sample of elderly adults attending senior center talks using the 7-item Research Attitudes Questionnaire (RAQ). Presentations on cognitive aging were given at centers, and 123 attendees completed RAQ-7. On trust safety questions, significant (42-48%) responded neutrally or negatively. Encouragingly, questions concerning importance research, 72-81% answered positively. More...
Objective: This study aims to evaluate the performance of a Chinese version Montreal Cognitive Assessment (MoCA) as screener detect mild cognitive impairment (MCI) and dementia from normal cognition in monolingual Chinese-speaking immigrant population. Method: A cohort 176 older adults National Alzheimer’s Coordinating Center Uniform Data Set is used for analysis. We explore impact demographic variables on MoCA calculate optimal cutoffs detection MCI with appropriate adjustment. Results:...
Retaining participants in longitudinal research aging and Alzheimer's disease remains a significant challenge. "Study partners" are often required to insure participation accuracy of information because cognitive impairment may interfere with accurate reporting. The purpose the present report was identify attitudes reasons for continued observational research.53 individuals (33 20 study partners) who were participating cohort at Mount Sinai Disease Research Center available this survey. They...
Racial/ethnic disparities in anti-dementia medications use longitudinally followed research participants are unclear.The study included initially untreated National Alzheimer's Coordinating Center Uniform Data Set who were ≥65 at baseline with disease dementia.Outcomes for acetylcholinesterase inhibitor (AChEI) treatment (1) any new AChEI during follow-up, and (2) persistence of follow-up categorized into: intermittent (< 50% follow-ups reporting treatment), persistent (≥50% follow-ups),...
ABSTRACT Background: Physicians often miss diagnosis of mild cognitive impairment (MCI) or early dementia and screening measures can be insensitive to very impairments. Other assessments may take too much time frustrating seniors. This study examined the ability an audio-recorded scale, developed in Australia, detect MCI Alzheimer's disease (AD) compared domain-specific performance on scale in-person battery common screens. Method: Seventy-six patients from Mount Sinai Disease Research...